An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Trial Profile

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2018

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Acronyms FREEDOM extension
  • Sponsors Amgen
  • Most Recent Events

    • 22 Apr 2018 Results assessing long-term fracture rates up to 10 years presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 22 Apr 2018 Results evaluating invasive oral procedures and events presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 16 Apr 2018 Results (n=138) assessing effects of up to 10 years of denosumab on bone histology, bone remodeling, and bone matrix mineralization characteristics from Freedom and Freedom extension studies, published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top